Select
Effects of Circular RNA hsa_circ_0001922 on Proliferation, Migration and Invasion of Prostate Cancer Cells and Its Potential Molecular Mechanism
ZHANG Yanyan, ZHAO Min, LIU Jing, GUO Hongyan, HU Yinying, ZHAO Lin, WANG Zhigang
Cancer Research on Prevention and Treatment. 2022, 49 (07 ): 649-654.
DOI: 10.3971/j.issn.1000-8578.2022.21.1328
Objective To investigate the effect of circular RNA hsa_circ_0001922 on the proliferation, migration and invasion of prostate cancer cell PC-3 and its underlying molecular mechanism. Methods qRTPCR and RNA FISH were used to detect the expression level and localization of hsa_circ_0001922 in PC-3 cells respectively. After hsa_circ_0001922 was targeted inhibited, clone formation, Transwell assay and scratch assay were used to detect the proliferation, migration and invasion abilities of PC-3 cells. qRT-PCR and Western blot were used to detect the expression levels of EMT pathway-related molecules after inhibiting hsa_circ_0001922. Results The expression of circular RNA hsa_circ_0001922 was increased in PC-3 cells (P <0.01) and it existed in the cytoplasm and nucleus. The invasion, migration and invasion abilities were significantly weakened (P <0.05) after inhibiting hsa_circ_0001922; the expression of E-cadherin mRNA increased (P <0.05) while the mRNA level of Vimentin decreased (P <0.05). The results of Western blot were consistent with the above (both P <0.05). Conclusion The circular RNA hsa_circ_0001922 may promote the proliferation, migration and invasion of PC-3 cells through the EMT pathway.
Select
Mechanism of Astragaloside IV on HepG2 Cells Based on Molecular Dynamics Simulation and Experimental Evaluation
ZHOU Zhipeng, YANG Mingzhu, CAI Mingqin, XUE Juandi, LYU Xiaoyun
Cancer Research on Prevention and Treatment. 2022, 49 (07 ): 655-661.
DOI: 10.3971/j.issn.1000-8578.2022.21.1537
Objective To reveal the mechanism of action of AS-IV on HepG2 cells based on molecular dynamics simulation and experimental evaluation. Methods We constructed a “drug-disease” network pharmacological map, analyzed the core genes of astragaloside IV (AS-IV) in HCC, screened key signaling pathways, and established a “drug-target” molecular dynamics model. In vitro assay was used to detect migration, proliferation and invasion abilities. Flow cytometry and qRT-PCR were used to detect the effect of AS-IV on the cell cycle and apoptosis, and the expression of core gene of HepG2. Results The core target of AS-IV acting on HCC was VEGFA. Compared with the control group, the high concentration of ASIV significantly inhibited the migration, invasion and proliferation of HepG2 cells, blocked the metastasis of HepG2 cells from G1 to G2 phase, promoted their apoptosis, down-regulated VEGFA expression and upregulated TGF-β1 expression. Conclusion AS-IV may inhibit the proliferation of hepatocellular carcinoma cells through multi-target and multi-pathway.
Select
Research Hotspots and Frontiers of Immunotherapy for Prostate Cancer: A Visual Analysis
JIN Tongtong, ZHOU Chuan, WANG Chao, DA Zijian, ZHOU Fenghai,
Cancer Research on Prevention and Treatment. 2022, 49 (07 ): 667-674.
DOI: 10.3971/j.issn.1000-8578.2022.21.1486
Objective To visualize and analyze the literature related to immunotherapy for prostate cancer published in the past 20 years through bibliometric analysis, and to explore the research progress and cuttingedge trends in this field. Methods The Web of Science core collection database was searched for literature related to immunotherapy for prostate cancer published from 2002 to 2021. CiteSpace and VOSviewer software were used to visualize and analyze the data and map the evolution of hotspots. Results There were 2 326 papers were finally included after excluding irrelevant studies. The field of immunotherapy for prostate cancer is in a rapid development stage; the United States has a great influence and China has a significant latecomer advantage; the National Cancer Institute, Memorial Sloan-Kettering Cancer Center and University of California, San Francisco are the main research institutions; American authors Gulley JL, Schlom J and Japanese author Itoh K have the highest number of publications. Currently, the main research hotspot is immune checkpoint inhibitors, and high-quality clinical trials are continuing to drive this process forward. Conclusion The exploration of novel immune pathways and the combination of different therapies will be the main trend of future research in immunotherapy for prostate cancer.
Select
Predictive Value of Depth of Invasion of Tongue Squamous Cell Carcinoma for Cervical Lymph Node Metastasis and Prognosis
XIA Lili, ZHU Xinyi, ZHANG Xiwei, LI Zhengjiang, LIU Shaoyan, LU Haizhen, AN Changming
Cancer Research on Prevention and Treatment. 2022, 49 (07 ): 675-681.
DOI: 10.3971/j.issn.1000-8578.2022.21.1460
Objective To investigate the predictive value of depth of invasion (DOI) of tongue squamous cell carcinoma (TSCC) for cervical lymph node metastasis and prognosis. Methods We retrospectively analyzed the clinical and pathological data of 73 patients with T1/2 TSCC. ROC curve was used to determine the optimal cut-off value of DOI for predicting cervical lymph node metastasis, and logistic regression analysis was performed to analyze the related factors affecting cervical lymph node metastasis of TSCC. Kaplan-Meier method and Cox regression analysis were used for survival analysis. Results Among 73 patients, 18 patients were with lymph node metastasis and 55 patients were without lymph node metastasis. The median DOI with and without lymph node metastasis were 8.00 and 5.00 mm, respectively (P =0.003). The optimal cut-off value for DOI was 6.15 mm, with AUC 0.75 (95%CI : 64.1%~87.1%, P =0.001), sensitivity 77.8% and specificity 63.6%. DOI and pathological differentiation were independent prognostic factors for cervical lymph node metastasis in multivariate analysis. DOI, nerve invasion and pathological differentiation were independent prognostic factors of survival in Cox regression analysis. Conclusion DOI of TSCC patients has important predictive value for both cervical lymph node metastasis and prognosis. Neck lymph node dissection is recommended for patients with DOI>6.15 mm to improve survival rate and reduce recurrence rate.
Select
Effect of Personality Characteristics on Near-term Postoperative Mental Health of Male Patients with Laryngeal Squamous Cell Carcinoma
AN Ning, FAN Daqing, YU Fangqin, MEI Zhidan
Cancer Research on Prevention and Treatment. 2022, 49 (07 ): 682-686.
DOI: 10.3971/j.issn.1000-8578.2022.21.1211
Objective To investigate the effect of personality characteristics on near-term postoperative mental health of patients with laryngeal squamous cell carcinoma (LSCC). Methods We included 119 patients with LSCC who underwent surgical treatment. The recent psychological state was assessed by SCL-90, SAS and SDS 5 to 7 days after surgery. The EPQ was used to evaluate the personality characteristics of patients after operation. Multiple linear stepwise regression method was used to analyze the influencing factors of SAS and SDS scores of LSCC patients. Results The postoperative scores of SCL-90, SAS and SDS of LSCC patients were significantly higher than the Chinese norm (P ≤ 0.05). The scores of P scale and N scale in EPQ were higher than the domestic norm (P <0.01). The scores of somatization, obsessiveness, anxiety, depression, hostility, phobia, paranoia and psychosis were significantly higher than the Chinese norm (P <0.05). Family income, surgical method, postoperative radiochemotherapy, psychoticism and neuroticism personalities were the influencing factors of postoperative SAS score (P <0.01). Family income, surgical method, postoperative radiochemotherapy, neurotic personality were the influencing factors of postoperative SDS score (P <0.01). Conclusion LSCC patients have near-term depression, anxiety and other psychological disorders after operation. In terms of personality, they have psychoticism and neuroticism. Family income, surgical methods, postoperative radiochemotherapy, psychoticism and neuroticism are independent risk factors affecting postoperative SAS and SDS scores.
Select
EGFR Mutation Status and PD-L1 Expression in Patients ≤ 40 Years Old with NSCLC
HU Mingming, LIU Zichen, ZHANG Hongmei, LU Baohua, LI Jie, WANG Qunhui, HU Fanbin, LIN Haifeng, LI Baolan, ZHANG Tongmei
Cancer Research on Prevention and Treatment. 2022, 49 (07 ): 687-691.
DOI: 10.3971/j.issn.1000-8578.2022.21.0969
Objective To retrospectively analyze the clinical data of 47 young NSCLC patients mutation style of EGFR and PD-L1 expression in tumor cells, to understand their clinicopathological and molecular characteristics. Methods We enrolled 47 young (≤ 40 years old) patients confirmed as NSCLC who underwent surgical resection, and 94 old patients (≥ 60 years old) were matched as 1:2 by R language. EGFR mutation status was detected by ARMS-PCR, and the expression of PD-L1 was detected by immunohistochemistry. Results The median age of 47 young patients with NSCLC was 37 years old. The disease was more common in women and the majority type was adenocarcinoma. In youth group, the 19del and 20ins were more frequent, but the exon 21 L858R point mutation proportion was higher in elder group. The expression of PD-L1 was significantly increased in the solid predominant histological subtype. The PD-L1 expression in 19del patients was higher than that in the patients with L858R mutation in youth group. Conclusion The majority of young NSCLC patients are female, nonsmokers and suffered from adenocarcinoma cancer. The proportion of EGFR alteration in 19del and 20ins in youth group is higher than that in elder group. The positive rate of PD-L1 expression in solid predominant histological subtype is higher than that with other subtypes. The expression of PD-L1 in young patients with EGFR 19del is higher than that with L858R.
Select
Expression and Significance of Serum DKK1 in Gastric Cancer Patients
ZHANG Rui, PENG Tao, YIN Jian, SONG Song, WANG Shen, MI Zihan, CHEN Wen, REN Jiansong
Cancer Research on Prevention and Treatment. 2022, 49 (07 ): 692-697.
DOI: 10.3971/j.issn.1000-8578.2022.21.1212
Objective To explore the expression and significance of serum DKK1 in patients with gastric cancer. Methods We selected 170 gastric cancer patients (gastric cancer group) and 170 subjects with nongastric cancer during the same period (control group). ELISA was used to detect the DKK1 level. The ROC curve was used to evaluate the diagnostic performance, and we analyzed the relation between DKK1 level and age, gender, family history of gastric cancer, cigarette smoking, alcohol consumption, tumor size, TNM stage, infiltration depth, lymph node metastasis, liver metastasis, vascular invasion, perineural invasion. Results The serum DDK1 level in GC patients was higher than that in control group (P <0.0001). ROC curve showed that the possible optimal cut-off value of DKK1 for gastric cancer patients was 167.8 pg/ml, AUC was 0.908, sensitivity was 80.59%, and specificity was 84.71%. There was no significant relation between the serum DKK1 level and age, gender, family history of gastric cancer, cigarette smoking, alcohol consumption, tumor size, liver metastasis, vascular invasion or distant metastasis (all P >0.05). However, DKK1 level was significantly related with TNM stage, infiltration depth, lymph node metastasis and perineural invasion (all P <0.05). Conclusion Serum DKK1 level is higher in gastric cancer patients than that of control group and related with the severity of lesions, which indicates that serum DKK1 may be a potential biomarker for gastric cancer screening.
Select
Efficacy and Adverse Reaction of Tislelizumab Combined with Chemotherapy on Urothelial Carcinoma
WEI Zongjie, KUANG Youlin, CHEN Yong, WANG Lu, CHEN Xiao, GOU Xin
Cancer Research on Prevention and Treatment. 2022, 49 (07 ): 698-702.
DOI: 10.3971/j.issn.1000-8578.2022.21.1340
Objective To evaluate the efficacy and safety of tislelizumab combined with chemotherapy in the treatment of urothelial carcinoma in the real word. Methods We enrolled 32 patients with urothelial carcinoma who were treated with tislelizumab and chemotherapy (gemcitabine/cisplatin or paclitaxel). The incidence of treatment-related adverse reactions during treatment and the efficacy evaluation were statistically analyzed. Results All patients were divided into two groups: 15 patients in the tislelizumab combined with paclitaxel group and 17 patients in the tislelizumab combined with GC group. Among 24 efficacy-evaluable patients, the ORR was 54.2% and the DCR was 83.3%. The ORR were 50.0% and 58.3%, and the DCR were 75.0% and 91.7% in the tislelizumab combined with paclitaxel group and the tislelizumab combined with GC group respectively. Common treatment-related adverse reactions included anemia (56.3%), loss of appetite (53.1%) and skin pruritus (50.0%). The grade 3-4 treatment-related adverse events occurred in 21.8% of patients. Common immune-related adverse reactions included skin toxicity (53.1%) and immune colitis (9.4%). Conclusion Tislelizumab combined with chemotherapy on urothelial cancer has significant curative effect, safety and controllability, but attention should be paid to immune-related adverse reactions.
Select
Recent Progress of Palbociclib in Treatment of HR+/HER2- Breast Cancer
ZHENG Fangchao, DU Feng, LIU Haolin, WANG Xue, YUE Jian, YUAN Peng
Cancer Research on Prevention and Treatment. 2022, 49 (07 ): 703-708.
DOI: 10.3971/j.issn.1000-8578.2022.22.0220
As the first cyclin-dependent kinases 4 and 6 inhibitors, palbociclib significantly improved the survival of the patients with the hormone receptor-positive and human epidermal growth factor receptor-2 negative breast cancer. Palbociclib is a crucial landmark in the development history of antineoplastic drugs. This article reviews the mechanism of palbociclib, and summarizes the clinical trials, side effects, and the application of palbociclib.
Select
Research Progress of Multi-target CAR-T Cell Therapy for Cancer
JIANG Yao, WEN Weihong, YANG Fa, NIE Disen, ZHANG Wuhe, QIN Weijun
Cancer Research on Prevention and Treatment. 2022, 49 (07 ): 709-714.
DOI: 10.3971/j.issn.1000-8578.2022.21.1224
Chimeric antigen receptor T cell (CAR-T) is a kind of adoptive cell immunotherapy, in which T cells are genetically modified to exert targeted killing effect on tumors. CAR-T cell therapy has shown remarkable antitumor efficacy for the treatment of tumors, especially for hematological malignancies, but is less effective in solid tumors. Single-target CAR-T is prone to off-target effect during application, and there is a risk of relapse or more refractory treatment. The development of double-target or multi-target CAR-T is expected to extend the antigen coverage of target cells, effectively avoids antigen escape and prevents tumor recurrence, and prolongs the survival time of patients. This article reviews the advances of multi-target chimeric antigen receptor T cell, and discusses the prospect of its development.
Select
Current Status and Prospects of Immunotherapy for Osteosarcoma
WU Wei, JING Doudou, CAO Li, PU Feifei, SHAO Zengwu
Cancer Research on Prevention and Treatment. 2022, 49 (07 ): 721-726.
DOI: 10.3971/j.issn.1000-8578.2022.21.1281
Osteosarcoma is a malignant tumor with extreme invasiveness and metastasis as well as dismal prognosis. It is critical to rapidly find a unique therapy strategy capable of significantly improving the prognosis of osteosarcoma. Tumor immunotherapy has the potential to reawaken the immune system, restart and sustain the tumor-immune cycle in the body, resulting in the death of tumor cells. CD8+ CTL, CD4+ T cells, NK cells and NKT cells all play critical roles in tumor immunity, while humoral immunity may not only inhibit tumor growth but also enhance it. Researchers have devised various strategies to boost the immune system in recent years based on tumor immune response studies. This paper highlights and examines osteosarcoma immunotherapy from two perspectives: (1) boosting the response of patient’s own immune system to the tumor; (2) exogenously improving the patient’s immunological function.
Select
Research Progress of Genes Related to Treatment and Prognosis of Alpha-fetoprotein Producing Gastric Cancer
LU Shunli, YU Jianping, CHEN Weikai, LI Andong, HE Qingyuan, CHEN Chao, HAN Xiaopeng
Cancer Research on Prevention and Treatment. 2022, 49 (07 ): 738-744.
DOI: 10.3971/j.issn.1000-8578.2022.21.1273
Alpha-fetoprotein producing gastric cancer (AFPGC) is a special type of gastric cancer. AFPGC is considered to be the most highly invasive tumor with a high degree of malignancy and prone to metastasis. As a consequence, it usually causes unsatisfied treatment effect and the prognosis is poor. At present, treatment methods and monitoring indicators have limited effect on AFPGC. VEGF, HER2, AFP, GPC3 and SALL4 are cogently associated with tumor genesis and development. If we can reasonably guide the treatment and prognosis of AFPGC patients, it will greatly improve the situation of patients and improve the survival of patients. This article reviews the research progress of the genes related to the treatment and prognosis of AFPGC.
18 articles
